BRPI0417369A - compostos de amida de ácido 3-amino-tieno[2,3-b]piridina-2-carboxìlico substituìdo como inibidores de ikk - Google Patents

compostos de amida de ácido 3-amino-tieno[2,3-b]piridina-2-carboxìlico substituìdo como inibidores de ikk

Info

Publication number
BRPI0417369A
BRPI0417369A BRPI0417369-4A BRPI0417369A BRPI0417369A BR PI0417369 A BRPI0417369 A BR PI0417369A BR PI0417369 A BRPI0417369 A BR PI0417369A BR PI0417369 A BRPI0417369 A BR PI0417369A
Authority
BR
Brazil
Prior art keywords
compounds
pyridine
acid amide
substituted
thieno
Prior art date
Application number
BRPI0417369-4A
Other languages
English (en)
Inventor
Zhidong Chen
Pier Francesco Cirillo
Darren Disalvo
Weimin Liu
Daniel Richard Marshall
Lifen Wu
Erick Richard Roush Young
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BRPI0417369A publication Critical patent/BRPI0417369A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"COMPOSTOS DE AMIDA DE áCIDO 3-AMINOTIENO¢2,3-B!PIRIDINA-2-CARBOXìLICO SUBSTITUìDO COMO INIBIDORES DE IKK". São apresentados os compostos de fórmula (1): em que a variáveis R~ 1~, R~ 2~, R~ 3~ e Z são aqui descritas, que são úteis como inibidores da atividade cinase do complexo I~K~B cinase (IKK). Os compostos são portanto úteis no tratamento de doenças mediadas por IKK íncluindo doenças autoimunes, doenças inflamatórias e câncer. Também são apresentadas composições farmacêuticas que compreendem estes compostos e processos para a preparação destes compostos.
BRPI0417369-4A 2003-12-05 2004-12-02 compostos de amida de ácido 3-amino-tieno[2,3-b]piridina-2-carboxìlico substituìdo como inibidores de ikk BRPI0417369A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52752203P 2003-12-05 2003-12-05
PCT/US2004/040888 WO2005056562A1 (en) 2003-12-05 2004-12-02 Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds as ikk inhibitors

Publications (1)

Publication Number Publication Date
BRPI0417369A true BRPI0417369A (pt) 2007-04-10

Family

ID=34676758

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417369-4A BRPI0417369A (pt) 2003-12-05 2004-12-02 compostos de amida de ácido 3-amino-tieno[2,3-b]piridina-2-carboxìlico substituìdo como inibidores de ikk

Country Status (16)

Country Link
US (3) US7119102B2 (pt)
EP (1) EP1692141A1 (pt)
JP (1) JP4557984B2 (pt)
KR (1) KR20070029643A (pt)
CN (1) CN1890249A (pt)
AR (1) AR047265A1 (pt)
AU (1) AU2004297250A1 (pt)
BR (1) BRPI0417369A (pt)
CA (1) CA2548011A1 (pt)
IL (1) IL176117A0 (pt)
MX (1) MXPA06005934A (pt)
PE (1) PE20050591A1 (pt)
RU (1) RU2006123704A (pt)
TW (1) TW200530252A (pt)
UY (1) UY28647A1 (pt)
WO (1) WO2005056562A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373424A1 (en) * 2002-06-06 2005-08-22 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
US7291733B2 (en) * 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
US7638519B2 (en) * 2003-12-23 2009-12-29 Myogen, Inc. Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
EP1926737B1 (en) 2005-09-15 2017-03-15 F. Hoffmann-La Roche AG 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
EP1965796A2 (en) * 2005-12-20 2008-09-10 Gilead Colorado, Inc. 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
EP2029608A1 (en) * 2006-06-06 2009-03-04 Boehringer Ingelheim International GmbH Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
JPWO2008020622A1 (ja) * 2006-08-17 2010-01-07 杏林製薬株式会社 新規なチエノ［２，３−ｄ］ピリミジン化合物
PE20090236A1 (es) 2007-04-06 2009-03-13 Neurocrine Biosciences Inc Antagonistas de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos
AR065948A1 (es) 2007-04-06 2009-07-15 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR100718830B1 (ko) * 1999-06-23 2007-05-17 사노피-아벤티스 도이칠란트 게엠베하 치환된 벤즈이미다졸 및 이의 제조방법
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
DE60229975D1 (de) * 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
EP1444010A2 (en) * 2001-10-30 2004-08-11 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
EP1478639A1 (en) * 2002-02-22 2004-11-24 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
US6974870B2 (en) 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
PL373424A1 (en) * 2002-06-06 2005-08-22 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
CA2534127A1 (en) * 2003-07-31 2005-02-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzothiophene compounds and uses thereof

Also Published As

Publication number Publication date
CA2548011A1 (en) 2005-06-23
US20050182053A1 (en) 2005-08-18
TW200530252A (en) 2005-09-16
UY28647A1 (es) 2005-07-29
MXPA06005934A (es) 2006-07-06
CN1890249A (zh) 2007-01-03
AR047265A1 (es) 2006-01-11
US7119102B2 (en) 2006-10-10
JP4557984B2 (ja) 2010-10-06
JP2007513187A (ja) 2007-05-24
RU2006123704A (ru) 2008-01-20
IL176117A0 (en) 2006-10-05
EP1692141A1 (en) 2006-08-23
PE20050591A1 (es) 2005-09-03
WO2005056562A1 (en) 2005-06-23
US20060270671A1 (en) 2006-11-30
KR20070029643A (ko) 2007-03-14
AU2004297250A1 (en) 2005-06-23
US20080312185A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
BR0311605A (pt) Compostos de amida de ácido 3-aminotieno[2,3-b]piridina-2-carboxìlico substituìdo e processos para preparação e seus usos
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
BR0312464A (pt) Inibidores de tirosina quinases
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
NO20056030L (no) Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
BR0017043A (pt) Imidazo[1,3,5]triazinonas e sua aplicação
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
MY150075A (en) Novel phosphodiesterase inhibitors
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
WO2005105753A8 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
BRPI0417369A (pt) compostos de amida de ácido 3-amino-tieno[2,3-b]piridina-2-carboxìlico substituìdo como inibidores de ikk
BR0307574A (pt) Derivados de nicotinamida úteis como inibidores de pde4
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
BRPI0509653A (pt) inibidores cinesina mitótica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.